Functional Activity of Enantiomeric Oximes and Diastereomeric Amines and Cyano Substituents at C9 in 3-Hydroxy-N-phenethyl-5-phenylmorphans
-
Published:2024-04-23
Issue:9
Volume:29
Page:1926
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Roth Hudson G.1, Das Madhurima1ORCID, Sulima Agnieszka1ORCID, Luo Dan2ORCID, Kaska Sophia2, Prisinzano Thomas E.2ORCID, Kerr Andrew T.3, Jacobson Arthur E.1ORCID, Rice Kenner C.1ORCID
Affiliation:
1. Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, Intramural Research Program, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services, 9800 Medical Center Drive, Bethesda, MD 20892-3373, USA 2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 789 S. Limestone Street, Lexington, KY 40536, USA 3. Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375-0001, USA
Abstract
The synthesis of stereochemically pure oximes, amines, saturated and unsaturated cyanomethyl compounds, and methylaminomethyl compounds at the C9 position in 3-hydroxy-N-phenethyl-5-phenylmorphans provided μ-opioid receptor (MOR) agonists with varied efficacy and potency. One of the most interesting compounds, (2-((1S,5R,9R)-5-(3-hydroxyphenyl)-2-phenethyl-2-azabicyclo[3.3.1]nonan-9-yl)acetonitrile), was found to be a potent partial MOR agonist (EC50 = 2.5 nM, %Emax = 89.6%), as determined in the forskolin-induced cAMP accumulation assay. Others ranged in potency and efficacy at the MOR, from nanomolar potency with a C9 cyanomethyl compound (EC50 = 0.85 nM) to its totally inactive diastereomer, and three compounds exhibited weak MOR antagonist activity (the primary amine 3, the secondary amine 8, and the cyanomethyl compound 41). Many of the compounds were fully efficacious; their efficacy and potency were affected by both the stereochemistry of the molecule and the specific C9 substituent. Most of the MOR agonists were selective in their receptor interactions, and only a few had δ-opioid receptor (DOR) or κ-opioid receptor (KOR) agonist activity. Only one compound, a C9-methylaminomethyl-substituted phenylmorphan, was moderately potent and fully efficacious as a KOR agonist (KOR EC50 = 18 nM (% Emax = 103%)).
Funder
National Institute on Drug Abuse
Reference18 articles.
1. (2024, March 13). SAMHSA.gov (Ed.) 2021 National Survey on Drug Use and Health (Nsduh), Available online: https://www.samhsa.gov/data/sites/default/files/2022-12/2021NSDUHFFRHighlights092722.pdf. 2. Spencer, M.R., Miniño, A.M., and Warner, M. (2022). Drug Overdose Deaths in the United States, 2001–2021, National Center for Health Statistics. NCHS Data Brief. 3. Probes for Narcotic Receptor Mediated Phenomena. 34. Synthesis and Structure-Activity Relationships of a Potent μ-Agonist δ−Antagonist and an Exceedingly Potent Antinociceptive in the Enantiomeric C9-Substituted 5-(3-Hydroxyphenyl)-N-Phenylethylmorphan Series;Hiebel;J. Med. Chem.,2007 4. G-Protein Biased Opioid Agonists: 3-Hydroxy-N-Phenethyl-5-Phenylmorphans with Three-Carbon Chain Substituents at C9;Gutman;RSC Med. Chem.,2020 5. Chambers, D.R., Sulima, A., Luo, D., Prisinzano, T.E., Goldberg, A., Xie, B., Shi, L., Paronis, C.A., Bergman, J., and Selley, D. (2022). A Journey through Diastereomeric Space: The Design, Synthesis, in Vitro and in Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists. Molecules, 27.
|
|